Pediatric rhabdomyosarcoma

Stephanie A Terezakis; Matthew Ladra

doi:10.1007/978-3-319-43545-9_3

Pediatric rhabdomyosarcoma

Stephanie A Terezakis, Matthew Ladra

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

Original language	English (US)
Title of host publication	Pediatric Oncology
Publisher	Springer Verlag
Pages	21-43
Number of pages	23
Edition	9783319435442
DOIs	https://doi.org/10.1007/978-3-319-43545-9_3
State	Published - Jan 1 2018

Publication series

Name	Pediatric Oncology
Number	9783319435442
ISSN (Print)	1613-5318
ISSN (Electronic)	2191-0812

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Oncology

Access to Document

10.1007/978-3-319-43545-9_3

Cite this

@inbook{531f635c35c944ddad53261b900b3420,

title = "Pediatric rhabdomyosarcoma",

abstract = "Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).",

author = "Terezakis, {Stephanie A} and Matthew Ladra",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/978-3-319-43545-9_3",

language = "English (US)",

series = "Pediatric Oncology",

publisher = "Springer Verlag",

number = "9783319435442",

pages = "21--43",

booktitle = "Pediatric Oncology",

edition = "9783319435442",

}

TY - CHAP

T1 - Pediatric rhabdomyosarcoma

AU - Terezakis, Stephanie A

AU - Ladra, Matthew

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

AB - Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

UR - http://www.scopus.com/inward/record.url?scp=85043249156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043249156&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43545-9_3

DO - 10.1007/978-3-319-43545-9_3

M3 - Chapter

AN - SCOPUS:85043249156

T3 - Pediatric Oncology

SP - 21

EP - 43

BT - Pediatric Oncology

PB - Springer Verlag

ER -

Pediatric rhabdomyosarcoma

Abstract

Publication series

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this